WSC
DNLI icon

Wellington Shields & Co’s Denali Therapeutics DNLI Stock Holding History

Wellington Shields & Co’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-75,000
Closed -$1.81M – 179
2020
Q2 		$1.81M Buy
+75,000
New +$1.76M 0.79% 32

Other funds holding DNLI

CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Shields & Co's DNLI Position: Q3 2020 in Review

Wellington Shields & Co sold out of Denali Therapeutics (DNLI) in Q3 2020, closing a stake of 75,000 shares — an estimated $1.81M sold.

Wellington Shields & Co first reported a position in DNLI in Q2 2020 and held it in 1 quarter. The position peaked at $1.81M in Q2 2020. 170 funds tracked by Wall St. Rank hold DNLI as of Q3 2020.

  • Wellington Shields & Co reported no remaining Denali Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Wellington Shields & Co sold 75,000 Denali Therapeutics shares in Q3 2020, an estimated $1.81M.
  • Wellington Shields & Co first reported a position in Denali Therapeutics in Q2 2020 and held it in 1 quarter.
  • Wellington Shields & Co's Denali Therapeutics position peaked at $1.81M in Q2 2020.
  • 170 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2020.

Based on Wellington Shields & Co's 13F filing for Q3 2020, filed 10 Nov 2020.